Review
References
|
Ai WZ, Tibshirani R, Taidi B, Czerwinski D, Levy R (2009). Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma. Blood 113:5743–5746. Crossref |
||||
|
Antony PA, Piccirillo CA, Akpinarli A (2005). CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174:2591-2601. Crossref |
||||
|
Armstrong AC, Easton D, Ewing JC (2001). Cellular Immunotherapy for Cancer. Br. Med. J. 323:1289-1293. Crossref |
||||
|
Bellamy CO, Malcomson RD, Harrison DJ, Wyllie AH (1995). Cell death in health and disease: the biology and regulation of apoptosis. Semin. Cancer Biol. 6(1):3–16. Crossref |
||||
|
Biragyn A, Ruffini PA, Leifer CA, Klyushnenkova E, Shakhov A, Chertov O, Shirakawa AK, Farber JM, Segal DM, Oppenheim JJ, Kwak LW (2002). Toll-like receptor 4- dependent activation of dendritic cells by betadefensin 2. Science 298(5595):1025–1029. Crossref |
||||
|
Biragyn A, Tani K, Grimm MC, Weeks S, Kwak LW (2001). Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J. Immunol. 167:6644–6653. Crossref |
||||
|
Bolhassani A, Rafati S (2008). Heat-shock proteins as powerful weapons in vaccine development. Expert. Rev. Vaccines 7:1185–1199. Crossref |
||||
|
Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GW, Westmoreland D, Evans AS, Adams M, Stacey SN, Boursnell ME, Rutherford E, Hickling JK, Inglis SC (1996). A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347:1523-1527. Crossref |
||||
|
Butts C Murray N, Maksymiuk A (2005). Randomized phase IIB trial of BLP25 liposome vaccine in stage III B and IV non-small-cell lung cancer. J. Clin. Oncol. 23(27):6674–6681. Crossref |
||||
|
Bronte V, Tsung K, Rao JB (1995). IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J. Immunol. 154:5282-5292. Pubmed |
||||
|
Campoli M, Ferrone S (2008). HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene 27:5869–5885. Crossref |
||||
|
Cereda V, Poole DJ, Palena C (2010). New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy. Cancer Immunol. Immunother. 59(1):63–71. Crossref |
||||
|
Chang DH, Dhodapkar MV (2003). Dendritic cells and immunotherapy for cancer. Int. J. Hematol. 77:439–443. Crossref |
||||
|
Coley WB (1893). The treatment of malignant tumors by repeated inoculations of erysipelas: With a report of ten original cases. Am. J. Med. Sci. 105:487-511. Crossref |
||||
| Cruise JM, Lewis RE (1999). The Thymus and T Lymphocytes, Atlas of Human Immunology. pp. 161-183. | ||||
|
Dranoff G, Jaffee E, Lazenby A (1995). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. 90:3539-3543. Crossref |
||||
|
Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002). Cancer immuno-editing: from immunosurveillance to tumor escape. Nat. Immunol. 3:991–998. Crossref |
||||
|
Falkow S, Isberg RR, Portnoy D (1992). The interaction of bacteria with mammalian cells. Annu. Rev. Cell Biol. 8: 333-363. Crossref |
||||
|
Franco A (2005). CTL-Based cancer Preventive therapeutic Vaccines for Carcinomas: Role of Tumour-Associated Carbohydrate Antigens. Scand. J. Immunol. 61:391-397. Crossref |
||||
|
Ganz T (2003). Defensins: antimicrobial peptides of innate immunity. Nat. Rev. Immunol. 3:710–720. Crossref |
||||
|
Gilboa E, Vieweg J (2004). Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol. Rev. 199: 251-263. Crossref |
||||
|
Greten TF, Jaffee EM (1999). Cancer Vaccines. American Society of Clinical Oncology. J. Clin. Oncol. 17:1047-1060. Pubmed |
||||
|
Hamilton SE, Wolkers MC, Schoenberger SP, Jameson SC, (2006). The generation of protective memory-like CD8+ T cells during homeostatic proliferation requires CD4+ T cells. Nat. Immunol. 7(5):475–481. Crossref |
||||
|
Higano CS, Schellhammer PF, Small EJ (2009). Integrated data from two randomized, double-blind, placebo controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate Cancer. Cancer 115:3670–3679. Crossref |
||||
|
Hoover HJ, Brandhorst JS, Peters LC (1993). Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-Year median follow-up of a phase III prospectively randomized trial. J. Clin. Oncol. 11:390-399. Pubmed |
||||
|
Hsu FJ, Caspar CB, Czerwinski D, Kwak LW, Liles TM, Syrengelas A, Taidi-Laskowski B, Levy R (1997). Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma: Long-term results of a clinical trial. Blood 89:3129-3135. Pubmed |
||||
|
Huang AY, Gulden PH, Woods AS (1996). The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc. Natl. Acad. Sci. 93:9730-9735. Crossref |
||||
|
Igney FH, Krammer PH (2002). Death and anti-death: tumour resistance to apoptosis. Nat. Rev. Cancer 2:277–288. Crossref |
||||
|
Janeway CA, Medzhitov R (2002). Innate immune recognition. Annu. Rev. Immunol. 20:197–216. Crossref |
||||
|
Janssen EM, Lemmens EE, Wolfe T (2003). CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421:852-856. Crossref |
||||
|
Jemal R, Siegel E, Ward Y, Hao J, Xu, TM (2009). Cancer statistics, 2009. CA Cancer J. Clin. 59:225–249. Crossref |
||||
|
Kalinski P, Urban J, Narang R, Berk E, Wieckowski, Muthuswamy R (2009). Dendritic cell-based therapeutic cancer vaccines: what we have and what we need. Future Oncol. 5:379–390. Crossref |
||||
|
Kershaw MH, Hsu C, Mondesire W, Parker LL, Wang G, Overwijk WW, Lapointe R, Yang JC, Wang RF, Restifo NP, Hwu P (2001). Immunization against endogenous retroviral tumor-associated antigens. Cancer Res. 61(21):7920–7924. Pubmed |
||||
|
Kessler J, Melief CJ (2007). Identification of T-cell epitopes for cancer immunotherapy. Leukemia 21(9):1859–1874. Crossref |
||||
|
Kitamura K, Livingston PO, Fortunato SR (1995). Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine. Proc. Natl. Acad. Sci. 92:2805-2809. Crossref |
||||
|
Krieg AM (2002). CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20:709–760. Crossref |
||||
|
Klinman DM, Barnhart KM, Conover J (1999). CpG motifs as immune adjuvants. Vaccine 17(1):19-25. Crossref |
||||
| Lesterhuis WJ, de Vries IJ, Adema GJ, Punt C (2004). Dendritic cell-based vaccines in cancer immunotherapy: an update on clinical and immunological results. Ann. Oncol. 15:145–151. | ||||
| Lin KY, Guarnieri FG, Staveley-O'Carroll K (1996). Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56:21-26. | ||||
|
Mansour W, Gilham DE, Thistlethwaite FC, Hawkins RE (2005). Engineering T Cells for Cancer Therapy. Br. J. Cancer 93(10):1085-1091. Crossref |
||||
|
Morse MA, Clay TM, Lyerly HK (2004). Biology of the Cancer Vaccine Immune Response. Handbook of Cancer Vaccines. Pp. 3-17. Crossref |
||||
|
Nel AE (2002). T-cell Activation through the Antigen Receptor. Part 1: Signaling components, Signaling Pathways, and Signal Integration at the T-cell Antigen Receptor Synapse. J. Allergy Clin. Immunol. 109:758-770. Crossref |
||||
|
Pan ZK, Ikonomidis G, Lazenby A (1995). A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours. Nat. Med. 1:471-477. Crossref |
||||
|
Pardoll DM (1995). Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol. 13:399-415. Crossref |
||||
|
Pardoll DM (2008). Cancer immunology. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG, (eds.), Abeloff's Clinical Oncology 4th ed. Philadelphia: Churchill Livingstone. pp. 140-147. Crossref |
||||
|
Peiser DE, Lienard D, Rufer N (2005). Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Investig. 115:739-746. Crossref |
||||
|
Plautz GE, Yang ZY, Wu BY (1993). Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc. Natl. Acad. Sci. 90:4645-4649. Crossref |
||||
| Plotkin SL, Plotkin SA (2008). A short history of vaccination. In: Plotkin SA, Orenstein WA, Offit PA (eds.), Vaccines 5th ed. New York: Elsevier. pp. 1–16. | ||||
|
Ragde H, Cavanagh WA, Tjoa BA (2004). Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer. J. Urol. 172:2532-2538. Crossref |
||||
| Restifo LL, Estes PS, Russo CD (1995). Genetics of ecdysteroid-regulated central nervous system metamorphosis in Drosophila, Diptera: Drosophilidae. Eur. J. Entomol. 92(1):169-187. | ||||
|
Rieger R, Kipps TJ (2003). CpG oligodeoxynucleotides enhance the capacity of adenovirus-mediated CD154 gene transfer to generate effective B-cell lymphoma vaccines. Cancer Res. 63:4128–4135. Pubmed |
||||
|
Robbins PF (2004). Tumor Antigen Discovery with T Cells Handbook of Cancer Vaccines. pp. 31-47. Crossref |
||||
|
Ruiz JP, Wolkowicz R,Waisman A (1998). Idiotypic immunization induces immunity to mutated p53 and tumor rejection. Nat. Med. 4:710-712. Crossref |
||||
|
Seliger B (2005). Strategies of tumor immune evasion. Biol. Drugs 19(6):347-54. Crossref |
||||
|
Small EJ, Schellhammer PF, Higano C (2006). Placebo-controlled phase III trial of immunologic therapy with Sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24:3089–3094. Crossref |
||||
|
So-Rosillo R, Small EJ (2006). Sipuleucel-T (APC8015) for prostate cancer. Expert Rev. Anticancer Ther. 6:1163–1167. Crossref |
||||
|
Stevenson FK, Rice J, Ottensmeier CH, Thirdborough SM, Zhu D (2004). DNA fusion gene vaccines against cancer. Clin. Immunol. Rev. 199:156-180. Crossref |
||||
| Tim FG, Elizabeth MJ (1999). Cancer Vaccines. J. Clin. Oncol. 17:1047-1060. | ||||
|
Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, van Beckhoven A, Liles TM, Engleman EG, Levy R (2002). Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in patients. Blood 99:1517–1526. Crossref |
||||
|
Townsend SE, Allison JP (1993). Tumor rejection after direct costimulation of CD81 T cells by B7- transfected melanoma cells. Science 259:368-370. Crossref |
||||
| Uzzo R, Cairns P, Dulin N, Horwitz E, Pollack A, Kolenko V (2003). Tumor resistance to apoptosis: Mechanisms of evasion and implications for radiation and chemotherapeutic strategies. In Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity and What Can Be Done. The Humana Press. pp. 215-233. | ||||
|
Vergati M, Intrivici C, Huen NY, Schlom J, Tsang K (2010). Review on Strategies for Cancer Vaccine Development. J. Biomed. Biotechnol. 59: 1-13. Crossref |
||||
|
von Boehmer H (2005). Mechanisms of suppression by suppressor T cells. Nat. Immunol. 6:338-344. Crossref |
||||
|
Weng WK, Czerwinski D, Timmerman J (2004). Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulinGFc receptor genotype. J. Clin. Oncol. 22:4717-4724. Crossref |
||||
| WHO (2014). World Health Organization. GLOBOCAN 2012: Estimated Cancer incidence, mortality and prevalence worldwide in 2012. IARC, 2014 Cancer Surveillance. | ||||
|
Wiemann B, Starnes CO (1994). Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol. Ther. 64:529–564. Crossref |
||||
|
Worboys M (2007). Vaccines: conquering untreatable diseases. B.M.J. 334:1-19. Crossref |
||||
|
Wu TC, Guarnieri FG, Staveley-O'Carroll KF (1995). Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc. Natl. Acad. Sci. 92:671-675. Crossref |
||||
|
Yang D, Chertov O, Bykovskaia SN, Chen Q, Buffo MJ, Shogan J, Anderson M, Schröder JM, Wang JM, Howard OM, Oppenheim JJ (1999). Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 286(5439):525–528. Crossref |
||||
|
Yokokawa J, Bera TK, Palena C (2007). Identification of cytotoxic T-lymphocyte epitope(s) and its agonist epitope(s) of a novel target for vaccine therapy (PAGE4). Int. J. Cancer 121:595–605. Crossref |
||||
|
Zepp F (2010). Principles of vaccine design-Lessons from nature. Vaccine 28 Suppl 3:C14-24. Crossref |
||||
|
Zitvogel L, Casares N, Péquignot M, Chaput N, Albert ML, Kroemer G (2004). The immune response against dying tumor cells. Adv. Immunol. 84:131–179. Crossref |
||||
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
